147 related articles for article (PubMed ID: 36435707)
1. Anaphylaxis: Revision of the Brighton collaboration case definition.
Gold MS; Amarasinghe A; Greenhawt M; Kelso JM; Kochhar S; Yu-Hor Thong B; Top KA; Turner PJ; Worm M; Law B
Vaccine; 2023 Apr; 41(15):2605-2614. PubMed ID: 36435707
[TBL] [Abstract][Full Text] [Related]
2. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.
Gold MS; Gidudu J; Erlewyn-Lajeunesse M; Law B;
Vaccine; 2010 Jun; 28(28):4487-98. PubMed ID: 20434547
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
Kochhar S; Assis DN; Mack C; Izurieta HS; Muratori L; Munoz A; Nordenberg D; Gidudu JF; Blau EF; Vierling JM
Vaccine; 2024 Mar; 42(7):1812-1825. PubMed ID: 38368225
[TBL] [Abstract][Full Text] [Related]
4. An algorithm developed using the Brighton Collaboration case definitions is more efficient for determining diagnostic certainty.
Joshi D; Alsentzer E; Edwards K; Norton A; Williams SE
Vaccine; 2014 Jun; 32(28):3469-72. PubMed ID: 24795227
[TBL] [Abstract][Full Text] [Related]
5. Adverse event reports of anaphylaxis after Comirnaty and Vaxzevria COVID-19 vaccinations, Western Australia, 22 February to 30 June 2021.
Shivarev A; Phillips A; Brophy-Williams S; Ford T; Richmond P; Effler P; McLean-Tooke A
Intern Med J; 2023 Feb; 53(2):275-279. PubMed ID: 36585764
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
Munoz FM; Cramer JP; Dekker CL; Dudley MZ; Graham BS; Gurwith M; Law B; Perlman S; Polack FP; Spergel JM; Van Braeckel E; Ward BJ; Didierlaurent AM; Lambert PH;
Vaccine; 2021 May; 39(22):3053-3066. PubMed ID: 33637387
[TBL] [Abstract][Full Text] [Related]
7. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
Iguchi T; Umeda H; Kojima M; Kanno Y; Tanaka Y; Kinoshita N; Sato D
Drug Saf; 2021 Nov; 44(11):1209-1214. PubMed ID: 34347278
[TBL] [Abstract][Full Text] [Related]
8. Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
Liu YC; Munoz FM; Izurieta HS; Tamborska AA; Solomon T; Law BJ; Chhabra N
Vaccine; 2023 Mar; 41(11):1902-1910. PubMed ID: 36775774
[TBL] [Abstract][Full Text] [Related]
9. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.
Cheng DR; Perrett KP; Choo S; Danchin M; Buttery JP; Crawford NW
Vaccine; 2015 Mar; 33(13):1602-7. PubMed ID: 25698493
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
Gollamudi J; Sartain SE; Navaei AH; Aneja S; Kaur Dhawan P; Tran D; Joshi J; Gidudu J; Gollamudi J; Chiappini E; Varricchio F; Law B; Munoz FM
Vaccine; 2022 Oct; 40(44):6431-6444. PubMed ID: 36150973
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of national institute of allergy and infectious diseases/food allergy and anaphylaxis network criteria for the diagnosis of anaphylaxis in emergency department patients.
Campbell RL; Hagan JB; Manivannan V; Decker WW; Kanthala AR; Bellolio MF; Smith VD; Li JT
J Allergy Clin Immunol; 2012 Mar; 129(3):748-52. PubMed ID: 22051698
[TBL] [Abstract][Full Text] [Related]
12. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
[TBL] [Abstract][Full Text] [Related]
13. Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
Serazin NA; Edem B; Williams SR; Ortiz JR; Kawade A; Das MK; Šubelj M; Edwards KM; Parida SK; Wartel TA; Munoz FM; Bastero P
Vaccine; 2021 May; 39(22):3028-3036. PubMed ID: 33583673
[TBL] [Abstract][Full Text] [Related]
14. Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
Deng L; Tapper K; Thosar D; Goeman E; Baker L; Adelstein S; Boyle M; Brown DA; Evans L; Katelaris C; Lee F; Li J; Swaminathan S; Taylor MS; Wong M; Wood N
Vaccine; 2023 Sep; 41(41):5987-5993. PubMed ID: 37633752
[TBL] [Abstract][Full Text] [Related]
15. Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021.
Lee E; Lee YK; Kim TE; Hwang I; Jung YH; Lee HR; Song J; Park Y; Cho E; Lee YK
Euro Surveill; 2021 Aug; 26(33):. PubMed ID: 34414880
[TBL] [Abstract][Full Text] [Related]
16. Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study.
Fitzpatrick T; Yamoah P; Lacuesta G; Sadarangani M; Cook V; Pourshahnazari P; Kalicinsky C; Upton JEM; Cameron SB; Zaborniak K; Kanani A; Lam G; Burton C; Constantinescu C; Pernica JM; Abdurrahman Z; Betschel S; Drolet JP; De Serres G; Quach C; Des Roches A; Chapdelaine H; Salvadori MI; Carignan A; McConnell A; Pham-Huy A; Buchan CA; Cowan J; Hildebrand K; Top KA;
Vaccine; 2024 Jun; ():. PubMed ID: 38910092
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of two case definitions for anaphylaxis: a comparison using a retrospective case notes analysis in the UK.
Erlewyn-Lajeunesse M; Dymond S; Slade I; Mansfield HL; Fish R; Jones O; Benger JR
Drug Saf; 2010 Jan; 33(1):57-64. PubMed ID: 20000867
[TBL] [Abstract][Full Text] [Related]
18. [Adverse events following vaccination].
Okada K
Nihon Rinsho; 2011 Sep; 69(9):1639-43. PubMed ID: 21922767
[TBL] [Abstract][Full Text] [Related]
19. Sensorineural hearing loss (SNHL) as an adverse event following immunization (AEFI): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
Carol Liu YC; Ibekwe T; Kelso JM; Klein NP; Shehu N; Steuerwald W; Aneja S; Dudley MZ; Garry R; Munoz FM;
Vaccine; 2020 Jun; 38(30):4717-4731. PubMed ID: 32418788
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
Rouleau I; De Serres G; Drolet JP; Skowronski DM; Ouakki M; Toth E; Landry M; Ménard S; Gagnon R
Vaccine; 2013 Dec; 31(50):5989-96. PubMed ID: 24144473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
